Replies to post #255883 on Biotech Values

[DewDiligence]

In_yet_another “Chevron” case, US District Court overrules FTC, allowing SRDX to be acquired by private-equity firm GTCR:

https://www.businesswire.com/news/home/20251110939371/en/Surmodics-Announces-U.S.-District-Court-Denies-Request-for-Preliminary-Injunction-to-Block-Proposed-Acquisition-by-GTCR

The buyout price is $43.0/sh cash, a 41% premium to SRDX closing price prior to the 5/29/24 announcement of the deal (https://www.gtcr.com/surmodics-enters-into-definitive-agreement-to-be-acquired-by-gtcr-for-43-00-per-share-in-cash-representing-an-approximate-equity-value-of-627-million/ ). The nominal deal value is $627M.

[DewDiligence]

VNDA—(+16%)—reports phase-2 data_in suppression of GLP_1 nausea/vomiting:

https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-positive-results-for-tradipitant-in-preventing-glp-1-induced-nausea-and-vomiting-302617739.html

https://www.clinicaltrials.gov/study/NCT06804603